Assessing proarrhythmic potential of environmental chemicals using a high throughput in vitro-in silico model with human induced pluripotent stem cell-derived cardiomyocytes
Article Sidebar
Main Article Content
Abstract
QT prolongation and the potentially fatal arrhythmia Torsades de Pointes are common causes for withdrawing or restricting drugs; however, little is known about similar liabilities of environmental chemicals. Current in vitro-in silico models for testing proarrhythmic liabilities, using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM), provide an opportunity to address this data gap. These methods are still low- to medium-throughput and not suitable for testing the tens of thousands of chemicals in commerce. We hypothesized that combining high-throughput population- based in vitro testing in hiPSC-CMs with a fully in silico data analysis workflow can offer sensitive and specific predictions of proarrhythmic potential. We calibrated the model with a published hiPSC-CM dataset of drugs known to be positive or negative for proarrhythmia and tested its performance using internal cross-validation and external validation. Additionally, we used computational down-sampling to examine three study designs for hiPSC-CM data: one replicate of one donor, five replicates of one donor, and one replicate of a population of five donors. We found that the population of five donors had the best performance for predicting proarrhythmic potential. The resulting model was then applied to predict the proarrhythmic potential of environmental chemicals, additionally characterizing risk through margin of exposure (MOE) calculations. Out of over 900 environmental chemicals tested, over 150 were predicted to have proarrhythmic potential, but only seven chemicals had a MOE < 1. We conclude that a high-throughput in vitro-in silico approach using population-based hiPSC-CM testing provides a reasonable strategy to screen environmental chemicals for proarrhythmic potential.
Plain language summary
This article discusses a new method for testing the potential harmful effects of environmental chemicals on the heart. We used human heart cells grown in a lab to test the chemicals and developed a computer model to predict their potential to cause dangerous heart rhythms. This method could help identify harmful chemicals more quickly and accurately than current testing methods. The study has the potential to improve evaluation of chemical risks and protect public health without the use of animals.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Articles are distributed under the terms of the Creative Commons Attribution 4.0 International license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the original work is appropriately cited (CC-BY). Copyright on any article in ALTEX is retained by the author(s).
Abdo, N., Xia, M., Brown, C. C. et al. (2015). Population-based in vitro hazard and concentration-response assessment of chemicals: The 1000 genomes high-throughput screening study. Environ Health Perspect 123, 458-466. doi:10.1289/ehp.1408775
Blanchette, A. D., Grimm, F. A., Dalaijamts, C. et al. (2019). Thorough QT/QTc in a dish: An in vitro human model that accurately predicts clinical concentration‐QTc relationships. Clin Pharmacol Ther 105, 1175-1186. doi:10.1002/cpt.1259
Blanchette, A. D., Burnett, S. D., Grimm, F. A. et al. (2020). A Bayesian method for population-wide cardiotoxicity hazard and risk characterization using an in vitro human model. Toxicol Sci 178, 391-403. doi:10.1093/toxsci/kfaa151
Blanchette, A. D., Burnett, S. D., Rusyn, I. et al. (2022). A tiered approach to population-based in vitro testing for cardiotoxicity: Balancing estimates of potency and variability. J Pharmacol Toxicol Methods 114, 107154. doi:10.1016/j.vascn.2022.107154
Blinova, K., Dang, Q., Millard, D. et al. (2018). International multisite study of human-induced pluripotent stem cell-derived cardiomyocytes for drug proarrhythmic potential assessment. Cell Rep 24, 3582-3592. doi:10.1016/j.celrep.2018.08.079
Burnett, S. D., Blanchette, A. D., Grimm, F. A. et al. (2019). Population-based toxicity screening in human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol 381, 114711. doi:10.1016/j.taap.2019.114711
Burnett, S. D., Blanchette, A. D., Chiu, W. A. et al. (2021a). Cardiotoxicity hazard and risk characterization of toxcast chemicals using human induced pluripotent stem cell-derived cardiomyocytes from multiple donors. Chem Res Toxicol 34, 2110-2124. doi:10.1021/acs.chemrestox.1c00203
Burnett, S. D., Blanchette, A. D., Chiu, W. A. et al. (2021b). Human induced pluripotent stem cell (iPSC)-derived cardiomyocytes as an in vitro model in toxicology: Strengths and weaknesses for hazard identification and risk characterization. Expert Opin Drug Metab Toxicol 17, 887-902. doi:10.1080/17425255.2021.1894122
Chiu, W. A., Wright, F. A. and Rusyn, I. (2017). A tiered, Bayesian approach to estimating of population variability for regulatory decision-making. ALTEX 34, 377-388. doi:10.14573/altex.1608251
Daley, M. C., Mende, U., Choi, B. R. et al. (2023). Beyond pharmaceuticals: Fit-for-purpose new approach methodologies for environmental cardiotoxicity testing. ALTEX 40, 103-116. doi:10.14573/altex.2109131
EMA – European Medicines Agency (2005). ICH S7B: The Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals CPMP/ICH/423/02.
Fermini, B., Hancox, J. C., Abi-Gerges, N. et al. (2016). A new perspective in the field of cardiac safety testing through the comprehensive in vitro proarrhythmia assay paradigm. J Biomol Screen 21, 1-11. doi:10.1177/1087057115594589
Gelman, A. and Rubin, D. B. (1992). Inference from iterative simulation using multiple sequences. Stat Sci, 457-472.
Gintant, G. (2011). An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation. Pharmacol Ther 129, 109-119. doi:10.1016/j.pharmthera.2010.08.008
Grimm, F. A., Klaren, W. D., Li, X. et al. (2020). Cardiovascular effects of polychlorinated biphenyls and their major metabolites. Environ Health Perspect 128, 077008. doi:10.1289/ehp7030
Guyton, K. Z., Kyle, A. D., Aubrecht, J. et al. (2009). Improving prediction of chemical carcinogenicity by considering multiple mechanisms and applying toxicogenomic approaches. Mutat Res 681, 230-240. doi:10.1016/j.mrrev.2008.10.001
ICH – International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (2018). Final Concept Paper: ICH S7B and E14 Q&A.
Krishna, S., Berridge, B. and Kleinstreuer, N. (2021). High-throughput screening to identify chemical cardiotoxic potential. Chem Res Toxicol 34, 566-583. doi:10.1021/acs.chemrestox.0c00382
Onakpoya, I. J., Heneghan, C. J. and Aronson, J. K. (2016). Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: A systematic review of the world literature. BMC Med 14, 10. doi:10.1186/s12916-016-0553-2
Patel, D., Stohlman, J., Dang, Q. et al. (2019). Assessment of proarrhythmic potential of drugs in optogenetically paced induced pluripotent stem cell-derived cardiomyocytes. Toxicol Sci 170, 167-179. doi:10.1093/toxsci/kfz076
Pearce, R. G., Setzer, R. W., Strope, C. L. et al. (2017). httk: R package for high-throughput toxicokinetics. J Stat Softw 79, 1-26. doi:10.18637/jss.v079.i04
Pognan, F., Beilmann, M., Boonen, H. C. et al. (2023). The evolving role of investigative toxicology in the pharmaceutical industry. Nat Rev Drug Discov 22, 317-335. doi:10.1038/s41573-022-00633-x
Ring, C. L., Arnot, J. A., Bennett, D. H. et al. (2018). Consensus modeling of median chemical intake for the US population based on predictions of exposure pathways. Environ Sci Technol 53, 719-732. doi:10.1021/acs.est.8b04056
Sager, P. T., Gintant, G., Turner, J. R. et al. (2014). Rechanneling the cardiac proarrhythmia safety paradigm: A meeting report from the cardiac safety research consortium. Am Heart J 167, 292-300. doi:10.1016/j.ahj.2013.11.004
Shah, R. R. (2002). The significance of QT interval in drug development. Br J Clin Pharmacol 54, 188. doi:10.1046/j.1365-2125.2002.01627.x
Sirenko, O., Grimm, F. A., Ryan, K. R. et al. (2017). In vitro cardiotoxicity assessment of environmental chemicals using an organotypic human induced pluripotent stem cell-derived model. Toxicol Appl Pharmacol 322, 60-74. doi:10.1016/j.taap.2017.02.020
Stockbridge, N., Morganroth, J., Shah, R. R. et al. (2013). Dealing with global safety issues: Was the response to QT-liability of non-cardiac drugs well coordinated? Drug Saf 36, 167-182. doi:10.1007/s40264-013-0016-z
Vargas, H. M., Rolf, M. G., Wisialowski, T. A. et al. (2021). Time for a fully integrated nonclinical-clinical risk assessment to streamline QT prolongation liability determinations: A pharma industry perspective. Clin Pharmacol Ther 109, 310-318. doi:10.1002/cpt.2029
Wang, B. and Zou, H. (2021). Honest leave‐one‐out cross‐validation for estimating post‐tuning generalization error. Stat 10, e413. doi:10.1002/sta4.413
Williams, A. J., Grulke, C. M., Edwards, J. et al. (2017). The CompTox chemistry dashboard: A community data resource for environmental chemistry. J Cheminform 9, 61. doi:10.1186/s13321-017-0247-6
Woosley, R. L., Chen, Y., Freiman, J. P. et al. (1993). Mechanism of the cardiotoxic actions of terfenadine. JAMA 269, 1532-1536.
Yang, X., Ribeiro, A. J., Pang, L. et al. (2022). Use of human iPSC-CMs in nonclinical regulatory studies for cardiac safety assessment. Toxicol Sci 190, 117-126. doi:10.1093/toxsci/kfac095